KineMed, Inc. Presents Innovative New Assays For Measurement Of In Vivo Cartilage Dynamics At The World Congress On Osteoarthritis

EMERYVILLE, Calif., Dec. 8 /PRNewswire/ -- KineMed, Inc., a platform-based indications discovery and development drug company, announced today that two posters detailing results from a new product program will be presented at the World Congress on Osteoarthritis meeting to be held in Boston, MA from December 8-11th, 2005.

The presentation information is as follows: Date: Friday, December 9th, 2005 Time: 1:30-3:00 pm, Eastern Standard Time Location: Marriott Copley Place, Poster Session I Titles of Presentations: “SIMULTANEOUS MEASUREMENT OF CELL AND MATRIX TURNOVER IN EXPERIMENTAL MODELS OF CARTILAGE DEGENERATION” (Poster # P63). “SYNOVIAL FLUID HYALURONAN: A POTENTIAL KINETIC BIOMARKER OF EARLY OSTEOARTHRITIS” (Poster # P61). KineMed KineMarker(TM) Product Programs in Osteoarthritis

KineMed’s proprietary in vivo KineMarker(TM) assays provide new, sensitive and high-throughput measures of several key pathways involved in the pathogenesis and treatment of degenerative joint conditions. These assays can be used in clinical as well as pre-clinical settings.

KineMed’s Cartilage Matrix KineMarkers(TM) are much more sensitive, reproducible and high-throughput than traditional methods, such as histological staining.

About KineMed, Inc.

KineMed, Inc. provides a proprietary set of tools for measuring the dynamics of molecular and cellular response to drugs in the intact organism, both in animals and humans. KineMed’s technology is ideally suited to enable the discovery of entirely new, unanticipated uses for compounds (an approach called repurposing or repositioning) by screening for activity in vivo across a wide variety of disease states. The breadth of therapeutic targets covered by KineMarker(TM) assays allows high-throughput screening in conditions beyond those typically evaluated. KineMed’s technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.

For further information about KineMed, please visit: http://www.kinemed.com

KineMed, Inc.

CONTACT: Lisa Misell, Ph.D., Vice President of Business Development ofKineMed, +1-510-655-6525, ext. 117, or Media: Justin Jackson, BurnsMcClellan, +1-212-213-0006, jjackson@burnsmc.com, for KineMed, Inc.

MORE ON THIS TOPIC